Last reviewed · How we verify
Methadone PCA
At a glance
| Generic name | Methadone PCA |
|---|---|
| Also known as | hyperalgesia-blocker |
| Sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Methadone as an Alternative Treatment for Children Underdoing HSCT (PHASE3)
- Perioperative Opioid-induced Hyperalgesia and Its Prevention With Ketamine and Methadone (NA)
- Postoperative Oral Methadone After Major Spine Surgery; Safety, Feasibility and Efficacy in Prevention of Progression to Chronic Opioid Usage at 3 Months (PHASE2, PHASE3)
- Methadone Pharmacokinetics in End-stage Renal Disease
- Perioperative Methadone Use to Decrease Opioid Requirement in Pediatric Spinal Fusion Patients (PHASE3)
- IONSYS Feasibility Study (PHASE4)
- A Prospective Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia (NA)
- Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methadone PCA CI brief — competitive landscape report
- Methadone PCA updates RSS · CI watch RSS
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano portfolio CI